

Programme

Thursday May 9

19.00-22.00 Welcome dinner at Comwell

Friday May 10

Morning

9.00 Welcome *President, Peter Ott (Aarhus)*

State of the art lectures

Chairs: Karl Heinz Weiss and Anil Dhawan

9.10 History of Wilson Disease *James Dooley (London)*

9.30 Diagnosis of WD in 2019 *Aftab Ala (Guildford)*

9.50 Classical and atypical neuro-psychiatric presentations *Tomasz Litwin (Warsaw)*

10.10 Specific challenges in pediatric Wilson patients *Eve A. Roberts (Toronto)*

10.30 Coffee break

Free papers

Chairs: Tomasz Litwin and Jan Pfeiffenberger

11.00 Major depressive disorder in patients with Wilson Disease and correlation with liver disease severity *Michelle A. Camarata (Guildford)*

11.15 Intestinal knockout of ATP7B impairs copper homeostasis *Sarah Guttman (Münster)*

11.30 Wilson Disease: The French pediatric cohort *Eduardo Couchonnal-Bedoya (Bron)*

11.45 Evolution of cognitive and psycho behavioral profile after a liver transplant in case of neurological aggravation *Carla Machado (Paris)*

12.00 Cardiac tissue characterization in patients with Wilson Disease using cardiac magnetic resonance imaging *Isabelle Mohr (Heidelberg)*

12.15 Lunch

Friday May 10

Afternoon

Genotype-phenotype part I. Genetic and non-genetic factors

Chairs: Roman S. Polishchuk and Roderick Houwen

13.15	ATP7B-/- mice as an animal model for Wilson Disease	<i>Svetlana Lutsenko (Baltimore)</i>
13.35	How to determine the functional consequences of a mutation using databases?	<i>Heinz Zoller (Innsbruck)</i>
13.55	Nongenetic factors modifying the phenotype	<i>Albert Friedrich Stättermayer (Vienna)</i>
14.15	Epigenetic factors in Wilson Disease	<i>Valentina Medici (Sacramento)</i>
14.35	Is WD a mitochondrial disorder?	<i>Hans Zischka (Munich)</i>
14.55	Coffee break and Poster session	

Genotype-phenotype part II. How frequent is WD?

Chairs: Radan Bruha and Oliver Bandmann

15.55	Genetic and clinical prevalence in UK	<i>Oliver Bandmann (Sheffield)</i>
16.10	Genetic and clinical prevalence in Sardinia	<i>Georgios Loudianos (Cagliari)</i>
16.25	Genetic and clinical prevalence in France	<i>Quentin Beaulieu (Paris)</i>
16.40	Analysis of the frequency and pathogenicity of ATP7B variants in a genomic dataset: Implications for Wilson Disease prevalence and penetrance	<i>Daniel Wallace (Brisbane)</i>

Chairs: Peter Ferenci and Lisbeth Birk Møller

16.55	Clinical profile and management of Wilson Disease among children and adolescents in an Indian Tertiary Care Centre	<i>Seema Alam (New Delhi)</i>
17.10	Genotype-phenotype correlation in India	<i>Harshad Devarbhavi (Bangalore)</i>
17.25	Does clinical and genetic data fit?	<i>Peter Ott (Aarhus)</i>
17.40	<u>Panel discussion</u> How frequent is WD. Is penetrance 100%?	
17.55	End of day	
19.00	Dinner at Ferdinand, Åboulevarden 28, 8000 Aarhus C	

Saturday May 11

Morning

Studying the mutated protein

Chairs: Stephen G. Kaler and Sven C.D. van Ijzendoorn

9.00	Mutant interactome as a target for rescue of ATP7B function in Wilson Disease	<i>Roman S. Polishchuk (Pozzuoli)</i>
9.20	Structural studies by single-particle cryo-electron microscopy	<i>Poul Nissen (Aarhus)</i>
9.40	Copper binding to human P-type ATPase ATP7B	<i>Nina Salustros (Copenhagen)</i>
9.55	Searching for a new treatment of Wilson Disease	<i>Christine J. F. Nielsen (Aarhus)</i>
10.10	Differentiation of pluripotent stem cells to bile canaliculi-forming hepatocytes to study genetic liver diseases involving hepatocyte polarity	<i>Arend W. Overeem (Groningen)</i>
10.25	Coffee break	

Assessing copper metabolism

Chairs: Svetlana Lutsenko and Valentina Medici

11.00	Quantifying changes in the KF-Ring	<i>Jesper Hjortdal (Aarhus)</i>
11.15	In exchangeable copper we trust	<i>Nouzha Djebrani-Oussedik (Paris)</i>
11.30	Calculated free copper is better	<i>Frederick K. Askari (Ann Arbor)</i>
11.45	Evaluation of human Copper metabolism and the diagnosis of Wilson Disease by $^{64}\text{CuCl}_2$ positron emission tomography	<i>Thomas Damgaard Sandahl (Aarhus)</i>
12.00	Substantia nigra hyperechogenicity change over time in patients with Wilson Disease	<i>Marta Skowronska (Warsaw)</i>
12.15	CRISPR/CAS9-mediated correction of mutated copper transporter ATP7B	<i>Vanessa Sandfort (Münster)</i>
12.30	Lunch	

Saturday May 11
Afternoon

Workshop Session 1:

Recommendations for clinical trials in WD

Chairs: Aurélie Poujois and Peter Ott

Moderators: Eve A. Roberts and Peter Ferenci

13.30	Topic 1	Potential study designs in orphan disease	<i>Ralf-Dieter Hilgers (Aachen)</i>
13.50	Moderator	Comments and questions	<i>Peter Ferenci (Vienna)</i>
14.00	Panel discussion		
14.30	Topic 2	Study Endpoints – Liver	<i>Michael L. Schilsky (New Haven)</i>
14.50	Moderator	Comments and questions	<i>Eve A. Roberts (Toronto)</i>
15.00	Panel discussion		
15.30	Coffee break		

Workshop Session 2:

Chairs: Frederick K. Askari and Aftab Ala

Moderators: Michael L. Schilsky and Karl Heinz Weiss

16.00	Topic 3	Study Endpoints – Neurology and quantifying neurological changes	<i>Anna Czlonkowska (Warsaw)</i>
16.20	Moderator	Comments and questions	<i>Michael L. Schilsky (New Haven)</i>
16.30	Panel discussion		
17.00	Topic 4	Monitoring the patients	<i>Peter Ferenci (Vienna)</i>
17.20	Moderator	Comments and questions	<i>Karl Heinz Weiss (Heidelberg)</i>
17.30	Panel discussion		
18.00	End of day		
18.30	Dinner at NO16, Europaplads 16, 8000 Aarhus C		

Sunday May 12

Morning

Treatment

Chairs: Eve A. Roberts and Piotr Socha

9.00	Treatment of Wilson Disease	<i>Peter Ferenci (Vienna)</i>
9.30	Liver transplantation in adults with WD	<i>Rodolphe Sobesky (Villejuif)</i>
9.45	Liver transplantation in children with WD	<i>Anil Dhawan (London)</i>
10.00	Controversy: Liver transplantation in neurologic disease	<i>Aurélia Poujois (Paris)</i>
10.15	Brain atrophy and neurological impairment in Wilson Disease	<i>Lukasz Smolinski (Warsaw)</i>
10.30	Coffee break	

Future treatments

Chairs: Anna Czlonkowska and Petr Dusek

11.00	Medical needs not addressed by current treatments	<i>Piotr Socha (Warsaw)</i>
11.15	Viral gene therapy for Menkes disease and related Copper Transport Disorders	<i>Stephen G. Kaler (Bethesda)</i>
11.30	Emerging therapies: hepatocyte transfer	<i>Sanjeev Gupta (Bronx)</i>
11.45	Evidence of Erad on ATP7B mutations indicates pharmacological chaperones as an optional individualized therapy for Wilson Disease	<i>Christina Hund (Rostock)</i>
12.00	Gene therapy	<i>Gloria González-Aseguinolaza (Pamplona)</i>
12.15	Closing remarks	<i>Peter Ott (Aarhus)</i>
12.25	Lunch	
13.30	Departure	